CLBT

ANALYST NOTE: CLBT (Cellebrite DI Ltd.) Date: 2026-06-13 Current Price: $12.83

1. Structural Readiness

• State: Forming
• Conservative Entry: Not yet triggered (awaiting confirmed breakout above the coil resistance).
• Aggressive/Pre-Breakout Entry: $12.83 (Current Price).
• Breakout Level: Pending confirmation above the coil resistance.
• Extension: N/A (Price is within the consolidation range, not extended).
• ATR Context: Current ATR is 5.3% (High). This indicates elevated volatility, which is consistent with a "forming" setup where price is compressing before a potential expansion.

2. Thesis Layer

• Thesis Status: TACTICAL / SETUP-LED.
• Analysis: As of 2026-06-13, there is no named secular thesis attached to this specific setup in the current data stream. The investment case is not driven by a macro-level thematic shift (e.g., "The AI Revolution" or "Global Security Crisis") but rather by the company's specific operational execution and the technical structure of the stock.
• Judgment Criteria: The conviction must be derived strictly from the quality of the setup (technical structure) and the strength of the underlying business fundamentals (revenue growth, margin expansion, cash position). Do not invent a macro narrative; judge the name on its ability to execute its stated guidance and maintain its structural integrity.

3. Business Overview

• Core Business: Cellebrite DI Ltd. is a leading provider of AI-powered digital investigative and intelligence solutions for legally sanctioned investigations globally. The company operates primarily in the software and services sector.
• Business Model: The company generates revenue primarily through annual and multi-year subscription agreements (E13).
• Customer Base: Sales to public safety agencies (law enforcement, defense, intelligence) account for more than 90% of revenue (E9). The client base includes federal, state, and local government bodies, as well as enterprise companies and service providers (E19).
• Key Offerings:
• UFED: Universal Forensic Extraction Device for accessing digital evidence (E17).
• Guardian Investigate: An AI-powered alternative to digital evidence management systems (E7).
• Seeker & OSINT Analyze: Tools for video analysis and open-source intelligence (E18).
• Crypto Tracer: Blockchain transaction deciphering (E18).
• Financial Performance (as of 2026):
• ARR: Grew 21% year-over-year to $493 million in Q1 2026 (E1).
• Guidance: Management expects ARR for Q2 2026 to be in the range of $510 million to $513 million (E5).
• Profitability: Adjusted EBITDA reached $30.6 million, up 29% year-over-year (E2).
• Growth Trajectory: Revenue grew from $271 million in 2022 to $476 million in 2025 (E10).
• Balance Sheet: As of Dec 31, 2025, the company held $124.5 million in cash, $161.0 million in short-term deposits, and $249.5 million in marketable securities (E11).
• Operational Updates: Management announced the early release of "Genesis" 90 days prior to planned general availability (E4) and expects to convert new products to bookings within weeks in the second quarter (E3).

4. Archetype and Conviction

• Archetype: Margin Inflector.
• Rationale: The company is demonstrating the ability to scale revenue (21% ARR growth) while simultaneously expanding margins (29% EBITDA growth). The shift toward AI-powered solutions (Guardian Investigate, Genesis) suggests a move toward higher-value, sticky software subscriptions, which typically inflects margins as the business scales.
• Valuation Context:
• Forward consensus EPS is estimated at $0.32795 for FY1 and $0.44164 for FY2 (E22).
• At a price of $12.83, the stock trades at approximately 39x FY1 EPS and 29x FY2 EPS. This valuation reflects the high growth rate (21% ARR) and the margin expansion, but it requires continued execution to justify.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro tailwind).
• Evidence Quality: High (Strong earnings data, clear guidance, robust balance sheet).
• Structural Quality: Moderate (Forming coil, high volatility).
• Rerating Potential: Moderate. The market may re-rate the stock if the "Margin Inflector" narrative holds and the breakout confirms, but the lack of a named secular thesis limits the ceiling for multiple expansion compared to pure-play AI leaders.

5. Invalidations, Strengths, and Gaps

• Strengthening: A confirmed breakout above the coil resistance with volume, coupled with a beat on Q2 ARR or EBITDA, would confirm the setup. Continued conversion of new products (Genesis, Guardian) to bookings as management expects (E3) would further strengthen the case.
• Gaps in Evidence:
• Detailed Margin Metrics: While EBITDA growth is cited, specific gross margin percentages or operating leverage details for 2026 are not explicitly broken out in the provided evidence.
• Customer Concentration Risk: While 90% of revenue is public safety, the specific concentration within that sector (e.g., reliance on a single large government contract) is not detailed.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: ARR grew 21% YoY to $493M with 29% EBITDA growth; Balance sheet is robust with over $535M in liquid assets; Setup is a forming coil with price holding above structural support. Key risks: Setup is not yet confirmed (breakout has not fired); High volatility (5.3% ATR) increases risk of false breakouts; No named secular thesis to support multiple expansion; Heavy reliance on public safety budget cycles. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" status and lack of macro thesis. Expected path: Management expects to convert new products to bookings in Q2; if ARR guidance is met and price breaks above the coil resistance, the setup transitions to confirmed. Expected horizon: 1 to 3 months for the breakout confirmation or invalidation.